Out-licensing
- Out-licensing
- View
Novel target anti-lung cancer siRNA therapies, treatment drugs
Mechanism of action
Full description
. Unique Merits of AIMP2 Targeting Anticancer Drugs
1. Previously Unexplored Target with Novel Working Mechanisms
(Global Initiatives in R&D and IP Position)
2. Generation of Tumorigenic Variant of AIMP2 Is Major Cause for Lung Caner
(Cancer-specific Target Available)
3. Suppression of AIMP2-DX2 Proven Effective against Lung Cancer
4. Small Chemical and siRNA Drug Candidates Are Available
5. Patents for Material and Usage Are Established Worldwide
. Our Products to develop
• Si-DX2 therapy -
– Specific AIMP2-DX2 inhibitor
– Aerosol inhalation administration
– Low toxicity and high efficiency of delivery
• Diagnostics
– Immuno histochemical Method
– QPCR AIMP2DX2 detection
– RISH detection system
– AIMP2 targeting small chemical drugs
– 4 drug candidates identified
Animal efficacy show
Development status
Patent information
AIMP2 Patent Portfolio:
|
Country |
Patent or Patent Application Title |
Patent or Patent Application Number |
|
United States |
Method for treating cancer using p38/JTV-1 and method for screening pharmaceutical composition for treating cancer |
US 2004/0175375 10/463,676 18 Jun 03
|
|
Europe |
Medical use of p38/JTV-1 |
EP 1454628 09 Sep 03 |
|
Japan |
Pharmaceutical composition for cancer therapy with p38/JTV-1 as active ingredient and method for screening the composition |
JP 2003-377932 07 Nov. 2003
|
|
Korea |
Pharmaceutical composition for treatment of cancer containing p38/JTV-1 as effective component and screening method of pharmaceutical composition for treatment of cancer |
KR 2003-18424 25th Mar 2003
|
AIMP2-DX2 Patent Portfolio:
|
Country |
Patent Application Title |
Patent Application Number |
|
Korea |
Use of AIMP2-DX2 for the diagnosis and treatment of cancer |
KR10-2005-0110946 18th March, 2005 |
|
Korea |
Use of AIMP2-DX2 for the diagnosis and treatment of cancer |
KR10-2006-0047831 26th May, 2006 |
|
International (PCT) |
Use of AIMP2-DX2 for the diagnosis and treatment of cancer |
PCT/KR2005/003924 18th March, 2005 |
|
United States |
AIMP2-DX2 and its uses |
US 11/264,725 1st Nov. 2005 |
|
Europe |
AIMP2-DX2 and its uses |
EP05819055.4 4th April, 2007 |
|
China |
AIMP2-DX2 and its uses |
CN200580037802.9 30th April, 2007 |
|
Japan |
AIMP2-DX2 and its uses |
JP2007-542907 24th May, 2007 |
Type of business relationship sought
1. Overseas Licensing Opportunity
2. Seeking potential corporate partners
Related reports
Licensing contact
Company details
KHIDI, provides various services on technology transfer. KHIDI will license and commercialise several technologies of KHIDI's client companies via collaboration with overseas partners.
View profileRelated technologies
- IntelliMab™
- In Vivo Non-Invasive Diagnostic Method Using Magnetic Resonance Spectroscopy of Aspartate Transaminase
- Doxycycline-Inducible B16 Melanoma Cell Lines Expressing CXCR4 or CCR10
- Radio-Activated Boron-Nitride Nanotube-Antibody Conjugates for Cancer Therapy and Diagnostics
- Treatment and Diagnosis of Cancer, Diabetes and Other Disorders Using Adrenomedullin Peptides and Antibodies
Related categories
- Industry sector
- Research tools / Antibodies
- Diagnostic / Antibody-based diagnostics
- Diagnostic / Biomarker-based diagnostics
- Research tools / Biomarkers
- Service / Clinical research
- Academic/Research / Diagnostic
- Biotechnology / Diagnostic test systems
- Academic/Research / Drug delivery
- Biotechnology / Gene therapy
- Research tools / Mouse models
- Academic/Research / Pharmaceutical
- Drug delivery / Pulmonary
- Drug delivery / Systemic
- Drug delivery / Topical
- Therapeutic target
- Oncology / Cancer (other)
- Oncology / Liver cancer
- Oncology / Lung cancer
- Oncology / Tumor (other)
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us